ClinicalTrials.Veeva

Menu

Effect of 12 Months Supplementation With a Symbiotic Lozenge on Caries Increment in Healthy Children (PiP-C)

C

Chr. Hansen

Status

Completed

Conditions

Dental Caries

Treatments

Dietary Supplement: Placebo
Dietary Supplement: 2 billion CFU in total of the two strains Lactobacillus paracasei subsp. paracasei and Lactobacillus rhamnosus and arginine.

Study type

Interventional

Funder types

Other
Industry

Identifiers

NCT03928587
HND-IM-034

Details and patient eligibility

About

The primary objective of this trial is to investigate the effect of a symbiotic lozenge on dental caries in young children.

Full description

The study is a multicentre, randomized, double-blind, placebo-controlled, parallel-group study in healthy children aged 5-8 years. The objective is to investigate the effect of a symbiotic lozenge on caries increment in primary molar teeth, primary canines and erupted occlusal surfaces at the first permanent molar teeth.The study will take place in Helsingør and Fredensborg municipality.

The study consists of a baseline visit prior to a 12 months intervention period, followed by a visit after completion. During the intervention period, two to four months after the baseline visit, a saliva sample will be collected.

All guardians to the subjects are encouraged to 1) brush their children's teeth twice daily with the fluoride toothpaste provided, 2) avoid the food provided in appendix D and 3) to continue the subject's dental appointments at local Public Dental Health Service (PDHS). No further specific oral hygiene or dietary instructions/restrictions are provided.

Assuming a dropout rate of 12.5%, 175 children will be included in each treatment group.

Enrollment

343 patients

Sex

All

Ages

5 to 8 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  1. Healthy children with absence of severe chronic disease
  2. Age 5-8 years, both inclusive, at inclusion
  3. Ability to cooperate at dental examination
  4. Ability to cooperate to a daily intake of a lozenge
  5. Parents/legal guarding provided voluntary written informed consent

Exclusion criteria

  1. Children with severe medical conditions
  2. Mentally or physically disabled children
  3. Children of parents with language barriers and not able to give written informed consent

Trial design

Primary purpose

Prevention

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Quadruple Blind

343 participants in 2 patient groups, including a placebo group

Active
Experimental group
Description:
A lozenge containing 2 billion CFU in total of the two strains Lactobacillus paracasei subsp. paracasei and Lactobacillus rhamnosus and arginine 2% to be taken once daily
Treatment:
Dietary Supplement: 2 billion CFU in total of the two strains Lactobacillus paracasei subsp. paracasei and Lactobacillus rhamnosus and arginine.
Placebo
Placebo Comparator group
Description:
An identical lozenge except for the absence of probiotics and arginine to be taken once daily.
Treatment:
Dietary Supplement: Placebo

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems